Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

Hematology 2009 Dec;14(6):323-30

Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina.

Objective: To determine the prevalence of JAK2 V617F mutation and its clinical correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).

Materials And Methods: Detection of JAK2 V617F mutation by allele specific-PCR.

Results: One hundred and three patients with CMD were included in the study. JAK2 V617F distribution was PV 40/45 (89%), ET 30/43 (69%), and IMF 7/15 (47%). In PV and ET patients only, 18 had thrombosis at diagnosis and 12 during follow-up (these were microvascular: 11, venous: 7 and arterial: 12); of these 28/70 (40%) were JAK2pos versus 2/18 (11%) JAK2neg; P=0.02. In a median of 4 years, two patients with PV JAK2pos evolved to myelofibrosis and one patient with PV presented in leukemic transformation (JAK2pos before and after transformation); six patients died: four patients with IMF and two patients with PV.

Conclusions: We found an association between JAK2 V617F and thrombotic events in patients with PV and ET.

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1179/102453309X124734
Publisher Site
http://dx.doi.org/10.1179/102453309X12473408860226DOI Listing
December 2009

Publication Analysis

Top Keywords

jak2 v617f
16
v617f mutation
12
patients
9
myeloproliferative disorders
8
patients chronic
8
chronic myeloproliferative
8
jak2
5
v617f
5
venous arterial
4
microvascular venous
4
follow-up microvascular
4
cmd included
4
diagnosis follow-up
4
arterial 28/70
4
versus 2/18
4
2/18 11%
4
jak2pos versus
4
40% jak2pos
4
28/70 40%
4
thrombosis diagnosis
4

Similar Publications